Angiotensin-(1–7) Modulates Renal Vascular Resistance Through Inhibition of p38 Mitogen-Activated Protein Kinase in Apolipoprotein E–Deficient Mice

Abstract

Abstract-Apolipoprotein E-deficient (apoE(−/−)) mice fed on Western diet are characterized by increased vascular resistance and atherosclerosis. Previously, we have shown that chronic angiotensin (Ang)(1-7) treatment ameliorates endothelial dysfunction in apoE(−/−) mice. However, the mechanism of Ang(1-7) on vasoconstrictor response to Ang II is unknown. To examine Ang(1-7) function, we used apoE(−/−) and wildtype mice fed on Western diet that were treated via osmotic minipumps either with Ang(1-7) (82 μg/kg per hour) or saline for 6 weeks. We show that Ang II-induced renal pressor response was significantly increased in apoE(−/−) compared with wildtype mice. This apoE(−/−)specific response is attributed to reactive oxygen species-mediated p38 mitogen-activated protein kinase activation and subsequent phosphorylation of myosin light chain (MLC 20 ), causing renal vasoconstriction. Here, we provide evidence that chronic Ang(1-7) treatment attenuated the renal pressor response to Ang II in apoE(−/−) mice to wildtype levels. Ang(1-7) treatment significantly decreased renal inducible nicotinamide adenine dinucleotide phosphate subunit p47phox levels and, thus, reactive oxygen species production that in turn causes decreased p38 mitogenactivated protein kinase activity. The latter has been confirmed by administration of a specific p38 mitogenactivated protein kinase inhibitor SB203580 (5 μmol/L), causing a reduced renal pressor response to Ang II in apoE(−/−) but not in apoE(−/−) mice treated with Ang(1-7). Moreover, Ang(1-7) treatment had no effect in Mas(−/−)/apoE(−/−) doubleknockout mice confirming the specificity of Ang (1-

Reversal of Bone Marrow Mobilopathy and Enhanced Vascular Repair by Angiotensin-(1-7) in Diabetes

“…The dose of ANG-(1-7) that we used was either similar or lower than the doses used in previous studies in mice (82 µg/kg/h s.c. for 6 weeks) (43,44). ANG-(1-7) at doses as low as 300 µg/kg/day s.c. potentiated the effects of NEUPOGEN on the recovery of circulating blood cells in mice after chemotherapy; however, higher doses of 1,200 µg/kg/day s.c. were needed for stimulating the recovery of progenitors of all lineages in the absence of NEUPOGEN (45).…”

Endotoxin-induced skeletal muscle wasting is prevented by angiotensin-(1–7) through a p38 MAPK-dependent mechanism

“…There is abundant evidence that Ang-(1-7) inhibits p38 MAPK phosphorylation by decreasing the deleterious effects of AngII in renal vasculature [60] and spinal nociceptive transmission [61], vascular smooth muscle cell proliferation [62] and vascular remodelling [63]. We have shown recently that Ang-(1-7), through the Mas receptor, can counteract the signalling induced by AngII in skeletal muscle fibrosis by decreasing p38 MAPK phosphorylation [43].…”

Angiotensin-(1-7)-induced Mas receptor activation attenuates atherosclerosis through a nitric oxide-dependent mechanism in apolipoproteinE-KO mice

“…In contrast, Ang-(1-7), recently recognized as another active metabolite of the renin angiotensin system which is cleaved from Ang I and Ang II by several endopeptidases and metalloproteinases like neprilysin and angiotensin converting enzyme 2 (ACE2) has been shown to counter regulate the pathophysiological effects of Ang II in cardiovascular diseases by activating its own receptor Mas [4,26]. Thus, chronic Ang-(1-7) infusion improved vascular function and attenuated the development of atherosclerosis by increasing NO-bioavailability, reducing vascular inflammation, immune cell response and VSMCs proliferation [6,10,17,18,28,16].…”